PharmTech Weekly Roundup - February 27, 2026

Welcome back to the PharmTech Weekly Roundup! The content team at PharmTech was busy again this week, and I’ve got a lot to share in just a few minutes, so be sure to check out the full articles and interviews on PharmTech.com.

Several key themes emerged this week: regulatory modernization at the FDA, a strategic pivot toward long-term CDMO partnerships, and the increasing use of AI and process patents as competitive moats. From the race for early-stage trial speed between the US and China to innovations in multi-dose delivery for high-demand obesity therapies (that’s right, the GLP-1s), I’m highlight the most critical messages for manufacturing and development professionals.

In response to FDA commissioner Marty Makary saying late last week that the US risks ceding leadership in early-stage drug development to China because of avoidable regulatory and operational delays in initiating clinical trials, Brian Scanlan, managing partner at Freedom Bioscience Partners told us that to remain globally competitive, the US must address regulatory bottlenecks in early-phase trial execution while CDMOs adopt AI-driven process development to narrow China's speed advantage.

Yet another big development in the booming area of GLP-1s dropped on Monday when Eli Lilly launched the multi-dose KwikPen for Zepbound, which could alleviate supply chain bottlenecks by reducing device component consumption and streamlining refrigerated distribution with its four doses that cover a full month.

In our Ask the Expert series, Siegfried Schmitt of Parexel International explained that updated regulatory guidelines from the European Commission and the FDA underscore that robust data governance remains the essential foundation for quality as manufacturing systems become increasingly digitalized.

GSK’s agreement to acquire 35pharma for $950 million, announced on Wednesday, targets the pulmonary hypertension market with a selective molecule designed to mitigate bleeding risks and provide secondary metabolic benefits.

In the article “How Innovation Is Reshaping Outsourced Development and Manufacturing,” from our Bio/Pharma Outsourcing Innovation eBook, Katie Edgar of KBI Biopharma says success in modern outsourced development is increasingly defined by "decision quality," with integrated CDMO models using multivariate analytics to evaluate scale-up feasibility and risks earlier in the lifecycle.

Asahi Kasei’s acquisition of Aicuris, announced on Thursday, concentrates investment into high-growth specialty therapeutics for immunocompromised patients and is a component of a broader strategy to transition toward a more capital-efficient structure by prioritizing high-growth pharmaceutical sectors.

The FDA introduced a significant regulatory shift with the release of draft guidance for the Plausible Mechanism Framework, which is meant to streamlines approvals for individualized therapies by allowing biological evidence and master protocols to replace traditional randomized controlled trials.

In an interview with PharmTech, Andrew Mitchell of BioVectra told us that the CDMO sector is experiencing a "boom" in new modalities like antibody-drug conjugates, RNA, and cell and gene therapies, creating a critical need for staff to upskill in IT and digital data analysis.

In another Bio/Pharma Outsourcing Innovation eBook article, Lars Hahn of Vetter writes that as drug pipelines become more injectable-heavy, biopharma companies are transitioning toward long-term, trust-based CDMO partnerships to de-risk development and ensure supply resilience.

Also from the Outsourcing Innovation eBook, our very own Susan Haigney explains that outsourced formulation services are shifting toward integrated full-service models to better manage the complexity of high-potency molecules and poorly soluble compounds.

In the first of new monthly series called Pharma Market Insights from Felix Gonzalez at FounderNest, he writes that manufacturing and formulation patents, particularly in polymorph engineering and continuous flow, have become core strategic tools for extending market exclusivity and durability.

Nathan Edwards and Michael Bianco of Arya Consulting Partners are back with part 4 of their 4-part article series on rare diseases. They say the economic advantages of rare disease development—including faster enrollment and regulatory flexibility—are driving biopharma buyers to engage in earlier Phase II transactions.

Continuing with the rare disease theme (Rare Disease Day is Feb 28), Elisabeth Gardiner of Tevard Biosciences explains in a video interview that research into ultra-rare conditions continues to yield critical genetic insights that lead to broad-spectrum therapeutic breakthroughs for the general population, such as PCSK9 inhibitors.

This week’s coverage on PharmTech.com highlights an industry in rapid transition. Whether it is adopting agentic AI for asset management or navigating the geopolitical shifts in clinical sourcing, the most successful organizations are those prioritizing technical discipline and strategic collaboration.